Back to other trials
Respiratory Syncytial Virus (RSV) is a common respiratory virus that typically causes mild, cold-like symptoms. However, it can be more severe in certain populations, such as infants, young children, and older adults, especially those with underlying health conditions. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under one year of age in the United States. The virus spreads through respiratory droplets when an infected person coughs or sneezes and can also survive on surfaces for several hours, making good hygiene practices crucial in preventing its spread. There is no specific treatment for RSV infections, and care is generally supportive. Efforts to develop a vaccine are ongoing, highlighting the significant impact of the virus on public health.
RSV Vaccine
ACRA is looking for participants who:

• are between the ages of 2 to < 18

• have one of the following conditions: Cystic fibrosis, Medically treated asthma, Other chronic respiratory diseases and malformations of the lung, Down syndrome, Neuromuscular disease, Cerebral palsy
Up to $600
2 to < 18
6 months